For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and Tafamidis meglumine represents a significant change. These novel therapies stabilize the transthyretin protein, halting its damaging build-up and alleviating the burden of the disease . Patients are now seeing positive out